Skip to content

Eton Pharmaceutical

US · ETON #2944 by market cap Listed 2018
60.85 -0.51 -0.83%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 21.21 Expensive vs history 80th percentile
5-year average 13.55 · #65 of 68 in Drug Manufacturers - Specialty & Generic
P/E ratio 41.51 Expensive vs history 85th percentile
5-year average -71.90 · forward 21.78 · #19 of 25 in Drug Manufacturers - Specialty & Generic
P/S ratio 13.07 Expensive vs history 93rd percentile
5-year average 6.51 · forward 6.81 · #70 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Eton Pharmaceutical (ETON) 1.76B 39.51 20.19 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value51.17 Economic moatNarrow UncertaintyHigh

Trading 15.9% above Morningstar's fair value estimate.

Fair value

Eton Pharmaceuticals Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 25% premium over our quantitative fair value estimate of $51.17 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's valuation metrics weaken our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 5.3%, which falls in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 3.0%, for example, falls in the bottom 45% globally. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

Economic moat

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.

Eton Pharmaceutical discussion 0 comments

Add a comment